Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

Sarepta Therapeutics presented new World Muscle Society data indicating ELEVIDYS delivered clinically meaningful functional benefit in ambulatory Duchenne muscular dystrophy patients treated at ages 8 to 12. The findings support the gene therapy's potential utility in an older patient group, where functional decline typically accelerates, and could strengthen its commercial and clinical positioning.

Analysis

The investable issue is whether the older ambulatory cohort expands ELEVIDYS' practical treatment pool and reduces the probability that prescribers reserve therapy for younger patients. If the functional signal is durable and supported by a credible control comparison, incremental uptake in the 8-12 age band could improve revenue visibility over the next 2-4 quarters and support multiple expansion from reduced label/penetration uncertainty. The key transmission channel is not merely additional patients: broader physician confidence should accelerate referrals before patients lose ambulation, improving treatment-center utilization and lowering commercial friction.

The evidence remains company-presented and the relevant question is statistical robustness rather than clinical adjectives. Investors should scrutinize patient count, follow-up duration, baseline matching, steroid-regimen balance, and whether functional outcomes exceed the natural-history decline expected in this age group; weak comparability would limit payer response even if the data are directionally favorable. Near-term upside may be capped if the market already assumes broad use, while any safety event, payer restriction, or evidence of declining benefit at longer follow-up would reintroduce substantial downside because SRPT remains concentrated in a single franchise.

Contrarian view: the more important read-through may be treatment timing rather than total addressable population. If physicians conclude benefit remains meaningful later, some families could defer treatment while awaiting additional safety data or reimbursement approval, temporarily slowing conversion despite a larger eligible cohort. Over 6-18 months, however, validated later-stage benefit would strengthen ELEVIDYS against emerging DMD approaches by making it harder for competitors to differentiate solely through access to older ambulatory patients.

Key Decisions for Investors

• Maintain a tactical long SRPT only through the next commercial-update and earnings window (1-3 months) if prescription/infusion-center commentary confirms broadening use in ages 8-12; target 15-25% upside on accelerated revenue expectations, with a 10-12% stop if payer-access metrics or treatment starts fail to improve.
• Do not add solely on the congress presentation. Require review of cohort size, duration, control methodology, and adverse-event detail; absence of a persuasive matched-control framework is a watch-item rather than a catalyst.
• Monitor quarterly ELEVIDYS net product revenue, treated-patient age mix, gross-to-net trend, and management's treatment-center capacity commentary. A revenue beat driven by inventory rather than treated patients would not validate the thesis.
• For defined-risk exposure into regulatory/safety uncertainty, prefer SRPT call spreads dated 3-6 months rather than unhedged equity; abandon the bullish setup following any material label restriction, serious safety signal, or guidance cut.